Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma

Summary

This is a Phase II, open-label, non-randomized, multicenter study to evaluate the clinical efficacy and safety of HG146 in participants with recurrent or metastatic adenoid cystic carcinoma. This study is divided into two stages. 40 participants will be enrolled in the first stage. The efficacy and safty data will apply to make go or no go decision. Then the second stage will continue to enroll 100 Particapants.

Timeline

Start

2024-12-13

Primary completion

2028-12-31

Completion

2029-06-30

Drugs

Indications